# Anticoagulation in Patients With Venous Thromboembolism and Cancer

> **NCT04618913** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Neoplasms
- Embolism

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban
- **DRUG:** Edoxaban
- **DRUG:** Dabigatran
- **DRUG:** VKA
- **DRUG:** LMWH

## Key facts

- **NCT ID:** NCT04618913
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-14
- **Primary completion:** 2026-04-06
- **Final completion:** 2026-04-06
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618913, "Anticoagulation in Patients With Venous Thromboembolism and Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04618913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*